Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested Case-Control Study and Meta-Analysis.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
18
08
2021
revised:
05
11
2021
accepted:
21
01
2022
pubmed:
29
1
2022
medline:
6
4
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
Endogenous sex hormones may contribute to higher colorectal cancer incidence rates in men compared with women, but despite an increased number of studies, clear evidence is lacking. We conducted a comprehensive nested case-control study of circulating concentrations of sex hormones, sex hormone precursors, and sex hormone binding globulin (SHBG) in relation to subsequent colon cancer risk in European men. Concentrations were measured using liquid LC/MS-MS in prospectively collected plasma samples from 690 cases and 690 matched controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS) cohorts. Multivariable conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). In addition, we conducted a meta-analysis of previous studies on men. Circulating levels of testosterone (OR, 0.68; 95% CI, 0.51-0.89) and SHBG (OR, 0.77; 95% CI, 0.62-0.96) were inversely associated with colon cancer risk. For free testosterone, there was a nonsignificant inverse association (OR, 0.83; 95% CI, 0.58-1.18). In a dose-response meta-analysis of endogenous sex hormone levels, inverse associations with colorectal/colon cancer risk were found for testosterone [relative risks (RR) per 100 ng/dL = 0.98; 95% CI, 0.96-1.00; I2 = 22%] and free testosterone (RR per 1 ng/dL = 0.98; 95% CI, 0.95-1.00; I2 = 0%). Our results provide suggestive evidence for the association between testosterone, SHBG, and male colon cancer development. Additional support for the involvement of sex hormones in male colon cancer.
Sections du résumé
BACKGROUND
Endogenous sex hormones may contribute to higher colorectal cancer incidence rates in men compared with women, but despite an increased number of studies, clear evidence is lacking.
METHODS
We conducted a comprehensive nested case-control study of circulating concentrations of sex hormones, sex hormone precursors, and sex hormone binding globulin (SHBG) in relation to subsequent colon cancer risk in European men. Concentrations were measured using liquid LC/MS-MS in prospectively collected plasma samples from 690 cases and 690 matched controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS) cohorts. Multivariable conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). In addition, we conducted a meta-analysis of previous studies on men.
RESULTS
Circulating levels of testosterone (OR, 0.68; 95% CI, 0.51-0.89) and SHBG (OR, 0.77; 95% CI, 0.62-0.96) were inversely associated with colon cancer risk. For free testosterone, there was a nonsignificant inverse association (OR, 0.83; 95% CI, 0.58-1.18). In a dose-response meta-analysis of endogenous sex hormone levels, inverse associations with colorectal/colon cancer risk were found for testosterone [relative risks (RR) per 100 ng/dL = 0.98; 95% CI, 0.96-1.00; I2 = 22%] and free testosterone (RR per 1 ng/dL = 0.98; 95% CI, 0.95-1.00; I2 = 0%).
CONCLUSIONS
Our results provide suggestive evidence for the association between testosterone, SHBG, and male colon cancer development.
IMPACT
Additional support for the involvement of sex hormones in male colon cancer.
Identifiants
pubmed: 35086823
pii: 1055-9965.EPI-21-0996
doi: 10.1158/1055-9965.EPI-21-0996
pmc: PMC9381125
doi:
Substances chimiques
Gonadal Steroid Hormones
0
Sex Hormone-Binding Globulin
0
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
793-803Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A29017
Pays : United Kingdom
Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Prev Res (Phila). 2018 Sep;11(9):535-544
pubmed: 29991578
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1336-1348
pubmed: 33879453
Am J Gastroenterol. 2021 Mar 1;116(3):522-529
pubmed: 33156012
Ann Oncol. 2014 Mar;25(3):712-718
pubmed: 24567517
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Endocrinol (Oxf). 2005 Sep;63(3):239-50
pubmed: 16117808
Clin Gastroenterol Hepatol. 2013 Apr;11(4):419-424.e1
pubmed: 23200979
Gut. 2012 Sep;61(9):1299-305
pubmed: 22027477
Horm Cancer. 2018 Dec;9(6):391-398
pubmed: 30097782
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Mol Med. 2011 Jan-Feb;17(1-2):48-58
pubmed: 20957335
Endocr Relat Cancer. 2011 Mar 09;18(2):265-76
pubmed: 21317201
J Clin Endocrinol Metab. 2007 Sep;92(9):3604-10
pubmed: 17579205
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1065-71
pubmed: 12376508
Discov Oncol. 2021 Mar 15;12(1):8
pubmed: 35201467
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Clin Endocrinol Metab. 2007 Jan;92(1):196-202
pubmed: 17062768
Cell Physiol Biochem. 2014;34(4):1402-12
pubmed: 25301365
Mol Cancer. 2009 Dec 01;8:114
pubmed: 19948074
J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70
pubmed: 21068432
Evid Based Ment Health. 2019 Nov;22(4):153-160
pubmed: 31563865
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42
pubmed: 16365013
J Clin Endocrinol Metab. 1981 Jul;53(1):58-68
pubmed: 7195404
Eur J Endocrinol. 2003 Dec;149(6):583-9
pubmed: 14641001
J Endocrinol. 1999 Jul;162(1):137-42
pubmed: 10396030
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16514-9
pubmed: 25368192
J Clin Endocrinol Metab. 2009 Jan;94(1):277-84
pubmed: 18840639
BMJ Open. 2017 Nov 15;7(11):e017639
pubmed: 29146641
J Natl Cancer Inst. 2015 Aug 01;107(10):
pubmed: 26232761
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
J Natl Cancer Inst. 1980 Dec;65(6):1201-7
pubmed: 7001123
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1262-9
pubmed: 15894683
Mol Cancer Ther. 2015 Apr;14(4):1066-74
pubmed: 25637315
N Engl J Med. 2009 Sep 17;361(12):1152-63
pubmed: 19657112
Am J Epidemiol. 1992 Jun 1;135(11):1301-9
pubmed: 1626547
Scand J Public Health Suppl. 2003;61:18-24
pubmed: 14660243
Int J Cancer. 2020 Aug 15;147(4):920-930
pubmed: 31863463
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):196-203
pubmed: 19124498
Horm Cancer. 2017 Apr;8(2):119-126
pubmed: 28233278
Int J Cancer. 2020 Oct 1;147(7):1881-1894
pubmed: 32181888
Public Health Nutr. 2003 Jun;6(4):407-13
pubmed: 12795830
Gastroenterology. 2020 Jul;159(1):241-256.e13
pubmed: 32247020
Cancer Epidemiol. 2020 Dec;69:101831
pubmed: 33038639
Cancer Control. 2015 Apr;22(2):263-70
pubmed: 26068776
Gut. 2019 Apr;68(4):672-683
pubmed: 29615487
Int J Cancer. 2021 Aug 1;149(3):573-584
pubmed: 33720423
Eur J Epidemiol. 2016 May;31(5):481-9
pubmed: 26758900
Trends Endocrinol Metab. 2015 Jul;26(7):376-83
pubmed: 26044465
Am J Med. 1999 May;106(5):574-82
pubmed: 10335731